Akero Therapeutics to be Acquired by Novo Nordisk for up to $5.2 Billion

SOUTH SAN FRANCISCO, Calif., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (“Akero”) (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that it has entered into a definitive agreement to be acquired by Novo Nordisk A/S (“Novo Nordisk”) for up to $5.2 billion in cash.

https://ir.akerotx.com/news-releases/news-release-details/akero-therapeutics-be-acquired-novo-nordisk-52-billion/